JY
APGE icon

Jeff Yass’s Apogee Therapeutics APGE Stock Holding History

Jeff Yass’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.9M Buy
202,800
+91,300
+82% +$8.23M ﹤0.01% 2138
2026
Q1 		$9.38M Buy
111,500
+69,800
+167% +$5.07M ﹤0.01% 3212
2025
Q4 		$3.15M Sell
41,700
-37,900
-48% -$2.39M ﹤0.01% 4801
2025
Q3 		$3.16M Sell
79,600
-73,100
-48% -$2.79M ﹤0.01% 4873
2025
Q2 		$6.63M Buy
152,700
+63,400
+71% +$2.41M ﹤0.01% 3484
2025
Q1 		$3.34M Buy
89,300
+36,100
+68% +$1.4M ﹤0.01% 4436
2024
Q4 		$2.41M Buy
53,200
+44,300
+498% +$2.26M ﹤0.01% 4888
2024
Q3 		$523K Buy
8,900
+100
+1% +$4.79K ﹤0.01% 8362
2024
Q2 		$346K Buy
+8,800
New +$427K ﹤0.01% 9134

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Jeff Yass's APGE Position: Q2 2026 in Review

Jeff Yass increased its Apogee Therapeutics (APGE) stake by 69% in Q2 2026, buying an estimated $1.01M and bringing the position to 27,256 shares worth $3.62M. The position accounts for ﹤0.01% of the portfolio, ranked #5240.

Jeff Yass first reported a position in APGE in Q4 2023 and has held it in 11 quarters since. 286 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Jeff Yass held 27,256 shares of Apogee Therapeutics worth $3.62M as of Q2 2026.
  • Jeff Yass bought 11,157 Apogee Therapeutics shares in Q2 2026, an estimated $1.01M.
  • Apogee Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5240 holding.
  • Jeff Yass first reported a position in Apogee Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 286 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.